Investigation Reveals Flaws in Cancer Drugs

The investigation by the Bureau of Investigative Journalism, published by The Hindu, has uncovered alarming revelations regarding the distribution of substandard cancer drugs globally. Below is a comprehensive summary of the findings, emphasizing critical details regarding the manufacturing and distribution of these essential medications:

Overview of the Investigation:

• A major investigation reveals that ineffective cancer drugs have been shipped to over 100 countries.
• The journey of cancer drugs involves multiple stages including raw material sourcing, manufacturing, packaging, distribution, and usage.

Quality Control Challenges:

• Protection against contamination and ensuring sterility during the manufacturing process are essential, but low- and middle-income countries often lack infrastructure and regulatory framework for quality assurance.
• Reports indicate that in nations like Nepal, limited resources result in ineffective monitoring and testing of imported medicines.

Incidents of Harm:

• Various tragic instances have been documented in recent years:
  • In 2019, five patients in Saudi Arabia fell seriously ill after receiving an Indian-made drug, resulting in one fatality.
  • In the same year, four children died, and over 100 fell ill in Colombia from similar substandard drugs.
  • In 2022, 10 children in Yemen died after being administered a contaminated chemotherapy drug.
  • In 2023, poor-quality brands of a childhood cancer drug were identified in Brazil.

WHO Efforts and Limitations:

• The World Health Organization (WHO) operates a rapid alert system for dangerous drugs but mainly identifies issues post-incident.
• Only seven countries in sub-Saharan Africa possess laboratories recognized by the WHO for drug testing, indicative of limited capabilities worldwide.

WHO Regulatory Frameworks:

Several mechanisms implemented by the WHO aim to enhance drug safety:

• Global Benchmarking Tool: Assesses national regulatory systems, with 70% of member countries rated at level 1 or 2, implying poor capacity for drug quality checks.
• Essential Medicines List: Prioritizes fundamental health system needs but may still include counterfeit medications.
• Prequalification Programs: Ensure that inspected drugs and laboratories meet safety standards.
• Good Manufacturing Practices (GMP) Certification: Mandates high-quality standards for pharmaceutical manufacturing.
• WHO Certification Scheme: Allows exporting countries to issue a Certificate of Pharmaceutical Products, validating the safety of medicines.

Effectiveness of Safety Measures:

• Current mechanisms provide some level of protection; however, they are inadequate compared to the rigorous oversight in countries like the UK.
• Testing of 84 drugs with CoPPs (Certificates of Pharmaceutical Products) intended for shipment from India to Nigeria revealed that all of them failed quality testing, illustrating systemic inefficiencies in ensuring drug safety.

Key Takeaways:

• The investigation underscores critical lapses in the drug supply chain, especially affecting low- and middle-income countries.
• The lack of stringent oversight and resources leads to numerous incidents endangering patient health due to substandard cancer drugs.
• Enhanced international cooperation and robust regulatory frameworks are essential for safeguarding drug quality and improving healthcare outcomes globally.

This investigation highlights the urgent need for developing stronger regulatory measures, especially in vulnerable regions, to prevent the distribution of harmful medications and protect public health.